KIDS (OrthoPediatrics Corp. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by KIDS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-10 | Samuel D Riccitelli | Director | A | — | — |
| 2026-06-10 | (Reynolds) Marie C Infante | Director | A | — | — |
| 2026-06-10 | David R Bailey | President and CEO | A | — | — |
| 2026-06-10 | Bryan W Hughes | Director | A | — | — |
| 2026-06-10 | Kelly Laine Fischer | Director | A | — | — |
| 2026-06-10 | Mark C Throdahl | Director | A | — | — |
| 2026-06-10 | Harold Ruf | Director | A | — | — |
| 2026-06-10 | George Sinclair Mitchell Dyer | Director | A | — | — |
| 2026-06-10 | Jimmy Duane McDonald | Director | A | — | — |
| 2026-06-10 | David R Pelizzon | Director | A | — | — |
| 2026-05-14 | Daniel J Gerritzen | General Counsel and Secretary | G | — | — |
| 2026-03-17 | David R Bailey | President and CEO | Sell | — | — |
| 2026-03-17 | Fred Hite | COO and CFO | MIXED | — | — |
| 2026-03-17 | Joseph W Hauser | Pres. Trauma & Def. Correction | MIXED | — | — |
| 2026-03-17 | Gregory A Odle | President of Scoliosis | MIXED | — | — |
| 2026-03-17 | Daniel J Gerritzen | General Counsel and Secretary | MIXED | — | — |
| 2025-12-30 | David R Bailey | President and CEO | G | — | — |
| 2025-11-12 | Kelly Laine Fischer | Director | A | — | — |
| 2025-08-25 | Fred Hite | COO and CFO | Buy | — | — |
| 2025-05-28 | Jimmy Duane McDonald | Director | A | — | — |
| 2025-05-28 | George Sinclair Mitchell Dyer | Director | A | — | — |
| 2025-05-28 | Bryan W Hughes | Director | A | — | — |
| 2025-05-28 | David R Pelizzon | Director | A | — | — |
| 2025-05-28 | Samuel D Riccitelli | Director | A | — | — |
| 2025-05-28 | Harold Ruf | Director | A | — | — |
| 2025-05-28 | Mark C Throdahl | Director | A | — | — |
| 2025-05-28 | (Reynolds) Marie C Infante | Director | A | — | — |
| 2025-05-28 | Terry D Schlotterback | Director | A | — | — |
| 2025-03-18 | Gregory A Odle | President of Scoliosis | MIXED | — | — |
| 2025-03-18 | Joseph W Hauser | Pres. Trauma & Def. Correction | MIXED | — | — |
| 2025-03-18 | Fred Hite | COO and CFO | MIXED | — | — |
| 2025-03-18 | David R Bailey | President and CEO | MIXED | — | — |
| 2025-03-18 | Daniel J Gerritzen | General Counsel and Secretary | MIXED | — | — |
| 2024-12-30 | David R Bailey | President and CEO | G | — | — |
| 2024-08-22 | Daniel J Gerritzen | General Counsel and Secretary | Sell | — | — |
| 2024-06-11 | Gregory A Odle | President of Scoliosis | A | — | — |
| 2024-06-11 | Fred Hite | COO and CFO | A | — | — |
| 2024-06-11 | Daniel J Gerritzen | General Counsel and Secretary | A | — | — |
| 2024-06-11 | Joseph W Hauser | Pres. Trauma & Def. Correction | A | — | — |
| 2024-06-11 | David R Bailey | President and CEO | A | — | — |
| 2024-06-11 | Mark C Throdahl | Director | A | — | — |
| 2024-06-10 | Harold Ruf | Director | G | — | — |
| 2024-06-10 | Harold Ruf | Director | MIXED | — | — |
| 2024-05-30 | Terry D Schlotterback | Director | A | — | — |
| 2024-05-30 | Jimmy Duane McDonald | Director | A | — | — |
| 2024-05-30 | Harold Ruf | Director | A | — | — |
| 2024-05-30 | Samuel D Riccitelli | Director | A | — | — |
| 2024-05-30 | George Sinclair Mitchell Dyer | Director | A | — | — |
| 2024-05-30 | (Reynolds) Marie C Infante | Director | A | — | — |
| 2024-05-30 | Bryan W Hughes | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 6,946,148 | — |
| — | 10%+ Owner | 6,901,764 | — |
| — | President and CEO | 417,160 | — |
| — | COO and CFO | 277,477 | — |
| — | Pres. Trauma & Def. Correction | 203,363 | — |
| — | Director | 201,814 | — |
| — | President of Scoliosis | 196,168 | — |
| — | General Counsel and Secretary | 147,054 | — |
| — | Director | 39,084 | — |
| — | Director | 32,663 | — |
| — | Director | 31,859 | — |
| — | Director | 31,202 | — |
| — | Director | 29,165 | — |
| — | Director | 26,940 | — |
| — | Director | 24,568 | — |
| — | Director | 24,568 | — |
| — | Director | 15,781 | — |
| — | Director | 14,291 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KIDS quote page; the site-wide leaderboard is on the insider transactions hub.